Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Unilateral HER2 Positive Breast Cancer × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 304 Carcinoma, Non-Small-Cell Lung 181 Ovarian Neoplasms 155 Lung Neoplasms 92 Esophageal Neoplasms 75 Triple Negative Breast Neoplasms 71 Stomach Neoplasms 70 Fallopian Tube Neoplasms 68 Squamous Cell Carcinoma of Head and Neck 50 Esophageal Squamous Cell Carcinoma 49 Neoplasm Metastasis 48 Neoplasms 45 Endometrial Neoplasms 42 Head and Neck Neoplasms 41 Carcinoma, Ovarian Epithelial 41 Uterine Cervical Neoplasms 37 Recurrence 26 Carcinoma, Squamous Cell 23 Adenocarcinoma Of Esophagus 21 Urinary Bladder Neoplasms 19 Prostatic Neoplasms 19 Melanoma 19 Inflammatory Breast Neoplasms 19 Adenocarcinoma of Lung 17 Carcinoma 15 Breast Neoplasms, Male 15 Unspecified Adult Solid Tumor, Protocol Specific 14 Testicular Neoplasms 13 Small Cell Lung Carcinoma 12 Peritoneal Neoplasms 12

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡